Opendata, web and dolomites


Detection of Various Cancer Types for Screening and Diagnosis through Blood Samples with Epigenetic Biomarkers Panels

Total Cost €


EC-Contrib. €






Project "EPICHECK" data sheet

The following table provides information about the project.


Organization address
postcode: 7670203
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-10-01   to  2016-03-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NUCLEIX LTD IL (REHOVOT) coordinator 50˙000.00


 Project objective

Nucleix developed a revolutionary platform for the development of Methylation Bio-markers and Bio-Marker panels for screening (early detection of disease) and diagnosis based on epigenetic markers. The platform identifies changes in specific methylation locations of DNA extracted from body fluids such as – urine, blood, stools and sputum. A Bio-Markers panel goal is to distinguish between sick and healthy individuals. The company’s expertise include the identification of the specific loci, comprising a panel of markers that can work in multiplex and generate highly accurate test. Nucleix technology was proven to be extremely sensitive and specific in its first application. Nucleix focuses initially on the field of cancer detection and screening. Cancer cost the EU €126 billion in 2009, which was 1.07% of EU GDP. 2.45m People in the EU were diagnosed with cancer in 2008, when 1.23 million people in the EU died from cancer in 2008. This is one of the most significant public health issues in the world and in the EU. Nucleix first product, Bladder EpiCheck is a urine test for the detection of Bladder Cancer. It is aimed for monitoring bladder cancer patients as this is a disease with high recurrence rate and requires tight surveillance. This product will be launched in Q4 of 2015. The test is based on a panel of 15 non-overlapping Methylation markers at loci that were identified, developed and owned by the company. This product which has better sensitivity and specificity than any other non-invasive test is a proof of the company’s ability to translate its technology to applicable products. The company plans to develop EPICHECK - diagnostic kits using multi-loci panel of markers, for the detection and screening of lung cancer and colorectal cancer in blood samples – which is the subject of this applications. EPICHECK will be launched rapidly, and will provide revenues of over 320m Euro in its 5th year of commercial activities.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPICHECK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPICHECK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More